With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

Girl rubbing her eyes

Bausch Health Companies Inc. stocks Bausch + Lomb Inc. with the first preservative-free OTC antihistamine eye drops approved in the US ahead of its planned spin-out of the eye health business.

The approval on 25 September of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after the Food and Drug Administration submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals Inc

More from Regulation

More from Policy & Regulation